-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明，无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Nymox Pharmaceutical (NASDAQ:NYMX) Earns Sell Rating From Analysts at StockNews.com
Nymox Pharmaceutical (NASDAQ:NYMX) Earns Sell Rating From Analysts at StockNews.com
StockNews.com started coverage on shares of Nymox Pharmaceutical (NASDAQ:NYMX – Get Rating) in a research report sent to investors on Saturday morning. The brokerage issued a sell rating on the biopharmaceutical company's stock.
Nymox Pharmaceutical Price Performance
Nymox Pharmaceutical stock opened at $0.32 on Friday. The company has a market capitalization of $28.96 million, a price-to-earnings ratio of -3.20 and a beta of 0.62. Nymox Pharmaceutical has a one year low of $0.19 and a one year high of $2.10. The company's fifty day moving average price is $0.36 and its two-hundred day moving average price is $0.38.
Get Nymox Pharmaceutical alerts:Nymox Pharmaceutical (NASDAQ:NYMX – Get Rating) last issued its quarterly earnings results on Monday, November 14th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter.
Institutional Investors Weigh In On Nymox Pharmaceutical
An institutional investor recently bought a new position in Nymox Pharmaceutical stock. Warberg Asset Management LLC purchased a new stake in Nymox Pharmaceutical Co. (NASDAQ:NYMX – Get Rating) during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 24,575 shares of the biopharmaceutical company's stock, valued at approximately $31,000. Hedge funds and other institutional investors own 0.78% of the company's stock.Nymox Pharmaceutical Company Profile
(Get Rating)
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma.
Featured Stories
- Get a free copy of the StockNews.com research report on Nymox Pharmaceutical (NYMX)
- Could 2023 Bring a Mega Comeback for MegaCaps?
- MarketBeat: Week in Review 12/26 – 12/30
- The Dogs Of Tech: It's Time For A Bite Of These Stocks
- Does This Acquisition Make Microsoft a Bear Market Buy?
- Is Kintara Therapeutics A Hidden Gem?
Receive News & Ratings for Nymox Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
StockNews.com started coverage on shares of Nymox Pharmaceutical (NASDAQ:NYMX – Get Rating) in a research report sent to investors on Saturday morning. The brokerage issued a sell rating on the biopharmaceutical company's stock.
StockNews.com 开始报道的股票 Nymox Pharmaceutical（纳斯达克：NYMX — 获取评级） 在周六上午发给投资者的研究报告中。该经纪公司对这家生物制药公司的股票发布了卖出评级。
Nymox Pharmaceutical Price Performance
Nymox 制药价格表现
Nymox Pharmaceutical stock opened at $0.32 on Friday. The company has a market capitalization of $28.96 million, a price-to-earnings ratio of -3.20 and a beta of 0.62. Nymox Pharmaceutical has a one year low of $0.19 and a one year high of $2.10. The company's fifty day moving average price is $0.36 and its two-hundred day moving average price is $0.38.
周五，Nymox制药的股票开盘价为0.32美元。该公司的市值为2896万美元，市盈率为-3.20，beta值为0.62。Nymox Pharmaceutical创下一年低点0.19美元，一年高点为2.10美元。该公司的五十天移动平均线价格为0.36美元，其两百天移动平均线价格为0.38美元。
Nymox Pharmaceutical (NASDAQ:NYMX – Get Rating) last issued its quarterly earnings results on Monday, November 14th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter.
Nymox Pharmaceutical（纳斯达克股票代码：NYMX — Get Ratinge）上次发布季度财报是在11月14日星期一。这家生物制药公司报告了本季度的每股收益（EPS）（0.02美元）。
Institutional Investors Weigh In On Nymox Pharmaceutical
机构投资者对 Nymox 制药表示关注
Nymox Pharmaceutical Company Profile
Nymox 制药公司简介
(Get Rating)
（获取评分）
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma.
Nymox Pharmaceutical Corporation是一家生物制药公司，在加拿大、美国、欧洲和国际上从事针对人口老龄化的药物的研究和开发。其主要候选药物是Fexapotide Triflutate（NX-1207），它已完成治疗良性前列腺增生的III期临床试验，低级别局部前列腺癌的II期临床试验，以及肝细胞癌的临床前研究。
Featured Stories
精选故事
- Get a free copy of the StockNews.com research report on Nymox Pharmaceutical (NYMX)
- Could 2023 Bring a Mega Comeback for MegaCaps?
- MarketBeat: Week in Review 12/26 – 12/30
- The Dogs Of Tech: It's Time For A Bite Of These Stocks
- Does This Acquisition Make Microsoft a Bear Market Buy?
- Is Kintara Therapeutics A Hidden Gem?
- 免费获取 StockNews.com 关于 Nymox Pharmaceutical（NYMX）的研究报告的副本
- 2023 年能否让 MegaCaps 卷土重来？
- MarketBeat：本周回顾 12 月 26 日 — 12 月 30 日
- 科技之狗：是时候咬一口这些股票了
- 此次收购会使微软成为熊市买入吗？
- 金塔拉疗法是隐藏的宝石吗？
Receive News & Ratings for Nymox Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nymox Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
接收《尼莫克斯制药日报》的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Nymox Pharmacearical及相关公司的最新新闻和分析师评级的简明每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Futu Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Futu Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国，moomoo上的投资产品和服务由Moomoo Financial Inc.提供，一家受美国证券交易委员会（SEC）监管的持牌主体。 Moomoo Financial Inc.是金融业监管局（FINRA）和证券投资者保护公司（SIPC）的成员。
在新加坡，moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供，该公司受新加坡金融管理局（MAS）监管(牌照号码︰CMS101000) ，持有资本市场服务牌照 (CMS) ，持有财务顾问豁免（Exempt Financial Adviser）资质。本内容未经新加坡金融管理局的审查。
在澳大利亚，moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供，该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构（AFSL No. 224663）。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件，这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大，通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供，并受加拿大投资监管机构（CIRO）监管。
在马来西亚，moomoo上的投资产品和服务是通过Futu Malaysia Sdn. Bhd. 提供，该公司受马来西亚证券监督委员会（SC）监管(牌照号码︰eCMSL/A0397/2024) ，持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Futu Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧